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PURPOSE. Increased corneal and epidermal Langerhans cells (LCs) have been reported in
patients with diabetic neuropathy. The aim of this study was to quantify the density of
LCs in relation to corneal nerve morphology and the presence of diabetic neuropathy
and to determine if this differed in patients with type 1 diabetes mellitus (T1DM), type
2 diabetes mellitus (T2DM), and latent autoimmune diabetes of adults (LADA).
METHODS. Patients with T1DM (n = 25), T2DM (n = 36), or LADA (n = 23) and control
subjects (n = 23) underwent detailed assessment of peripheral neuropathy and corneal
confocal microscopy. Corneal nerve fiber density (CNFD), branch density (CNBD), length
(CNFL) and total, immature and mature LC densities were quantified.
RESULTS. Lower CNFD (P < 0.001), CNBD (P < 0.0001), and CNFL (P < 0.0001) and higher
LC density (P = 0.03) were detected in patients with T1DM, T2DM, and LADA compared
to controls. CNBD was inversely correlated with mature (r = –0.5; P = 0.008), immature
(r = –0.4; P = 0.02) and total (r = –0.5; P = 0.01) LC density, and CNFL was inversely
correlated with immature LC density (r = –0.4; P = 0.03) in patients with T1DM but not
in patients with T2DM and LADA.
CONCLUSIONS. This study shows significant corneal nerve loss and an increase in LC density
in patients with T1DM, T2DM, and LADA. Furthermore, increased LC density correlated
with corneal nerve loss in patients with T1DM.
Keywords: Langerhans cells, corneal confocal microscopy, type 1 diabetes, type 2
diabetes, LADA
Diabetic peripheral neuropathy (DPN) is the most preva-lent complication of diabetes mellitus.1 The etiology
of diabetic neuropathy is complex, and, although hyper-
glycemia and hyperlipidemia are major drivers, recent stud-
ies suggest a significant contribution from immune and
inflammatory components.2 Corneal confocal microscopy
(CCM) is a non-invasive ophthalmic technique that has
been used to demonstrate corneal nerve loss in patients
with DPN.3 CCM can also be used to quantify Langerhans
cells (LCs) and stromal keratocytes4,5 in images comparable
with histochemical methods.6 Corneal LCs are professional
antigen-presenting cells of the cornea.7 LCs characterized
by a cell body and dendrites reside primarily in the basal
epithelium or sub-basal layer of the cornea with an aver-
age cell density of 21 to 34 cells/mm2 in the central cornea,
and they lie in close proximity to corneal nerve fibers.8
In healthy subjects, the majority of LCs are mature with
dendrites and are found in the peripheral cornea, whereas
immature LCs without dendrites are found in the central
cornea.9,10 Trauma, infection, and cytokines and chemokines
can lead to activation and maturation of LCs.11
Experimental and clinical studies support the role of
inflammation in the pathogenesis of DPN.12 Lauria et al.13
reported an increase in the number of LCs and a reduction
in the intraepidermal nerve fiber density in the footpad of
streptozotocin diabetic rats. Increased epidermal LC density
has been related to a loss of intraepidermal nerve fiber
density in patients with painful diabetic neuropathy.14 Exper-
imental studies have demonstrated an association between
increased LC density and corneal nerve fiber loss in murine
models of type 1 diabetes mellitus (T1DM) and type 2
(T2DM).15,16 We have shown an increase in corneal LC
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density in adults with mild diabetic peripheral neuropa-
thy17 and an increase in LC density and corneal nerve loss
in children with T1DM.4 We have previously shown more
severe DPN and greater corneal nerve loss in patients with
latent autoimmune diabetes in adults (LADA) compared with
patients with T2DM.18 The purpose of this study was to
assess if there are differences in the density of LCs and their




Subjects with T1DM (n = 25), T2DM (n = 36), or LADA (n
= 23) and healthy age-matched controls (n = 23) were stud-
ied. Patients with a history of connective tissue or infectious
disease, malignancy, deficiency of B12 or folate, chronic renal
or liver failure, current or active diabetic foot ulceration,
contact lens wear, or ocular or systemic disease (other than
diabetes) affecting the cornea were excluded. The research
adhered to the tenets of the Declaration of Helsinki and
was approved by the Greater Manchester Research Ethics
Committee. Each participant provided informed consent
prior to participation in the study.
Clinical and Peripheral Neuropathy Assessment
Lipid profile (total cholesterol, low-density lipoprotein and
high-density lipoprotein cholesterol, triglycerides), glycated
hemoglobin (HbA1c), and body mass index were measured
in each participant. The simplified neuropathy disability
score (NDS) was used to examine neurological deficits
for vibration, pinprick, temperature perception, and pres-
ence or absence of ankle reflexes.19 The neuropathy symp-
tom profile (NSP) was used to evaluate neurological symp-
toms20; it consists of 38 questions categorized into separate
groups of sensory dysfunction, autonomic neuropathy, and
weakness of the head and neck, chest, upper limbs, and
lower limbs. The vibration perception threshold (VPT) was
evaluated using a Neurothesiometer (Scientific Laboratory
Supplies, Wilford, Nottingham, UK) on the tip of a big toe.
A consultant neurophysiologist undertook electrodiagnostic
studies using a Dantec Keypoint system (Dantec Dynamics,
Skovlunde, Denmark) equipped with a thermistor (Dantec
DISA temperature regulator) to maintain the limb tempera-
ture between 32°C and 35°C. Peroneal motor nerve conduc-
tion velocity (PMNCV) was tested.
Corneal Confocal Microscopy
Prior to CCM examination, the ocular surface was assessed
using slit-lamp biomicroscopy. CCM examination was
performed for both eyes using laser scanning corneal confo-
cal microscopy (Retinal Tomograph III Rostock Cornea
Module, Heidelberg Engineering, Heidelberg, Germany)
following our published protocol.21 Six CCM images (three
per eye) of the corneal sub-basal nerve plexus from the
central cornea were selected for corneal nerve and LC evalu-
ation. The main criteria for the image selection were contrast
and quality of the image, position, depth of the sub-basal
nerve plexus, and absence of artifacts. Images were analyzed
using CCMetrics (The University of Manchester, Manchester,
UK) by a single expert in a masked manner.22 We quan-
tified corneal nerve fiber density (CNFD; total number of
main nerves per square millimeter [no./mm2]), corneal nerve
branch density (CNBD; total number of branches per square
millimeter [no./mm2]), corneal nerve fiber length (CNFL;
total length of main nerves and nerve branches per square
millimeter [mm/mm2]).23
The same six CCM images were also used to quantify LC
density. LCs were identified as bright, white structures.10 LCs
less than 50 μm in length with no dendritic structures were
defined as immature cells, and LCs with a length greater
than 50 μm and dendritic structures were defined as mature
cells. The total LC density (no./mm2) was quantified using
the NBD feature, and the length of the cell was quantified
using the NFL feature in CCMetrics.4
Statistical Analysis
The analysis was carried out using SPSS Statistics 22.0
for Windows (IBM Corporation, Armonk, NY, USA). The
Shapiro–Wilk test was employed to assess whether the data
were normally distributed. Based on their distribution, data
are expressed as mean ± standard deviation (SD) or as
median and interquartile range (IQR). Fisher’s exact test was
used to test the association between two categorical vari-
ables. Based on normality, Spearman and Pearson correla-
tions were used to test the association between CCM param-
eters and LC density. Analysis of variance with Bonferroni
correction was used to compare means among groups. P <
0.05 was considered significant. Graphs were created using
Prism 7.0 for Windows (GraphPad Software, La Jolla, CA,
USA).
RESULTS
Demographic and Laboratory Results
Demographic data are presented in Table 1. Age (P = 0.6)
and sex (P = 0.4) were comparable among the groups (Table
1). The duration of diabetes was significantly higher in the
T1DM group (19.4 ± 7.6 years) compared with the LADA
group (11.9 ± 9.6 years; P = 0.001) but was comparable to
that for the T2DM group (15.1 ± 4.9 years; P = 0.06). HbA1c
was significantly higher in patients with T1DM (63.0 ±
15.0 mmol/mol; P < 0.0001), LADA (83.0 ± 25.8 mmol/mol;
P < 0.0001), or T2DM (66.0 ± 15.4 mmol/mol; P < 0.0001)
compared with controls (35.4 ± 2.9 mmol/mol), and patients
with LADA had a significantly higher HbA1c compared with
T1DM (P = 0.001) and T2DM (P = 0.002). Patients with
T2DM had a significantly higher body mass index (31.7
± 5.2) compared with patients with T1DM (26.8 ± 4.4; P
= 0.001) or LADA (27.1 ± 4.4; P = 0.003) and controls
(27.4 ± 4.6; P = 0.006). Total cholesterol was significantly
lower in the T1DM (4.0 mmol/L; IQR, 3.5–4.7; P < 0.0001),
LADA (4.5 mmol/L; IQR, 3.8–5.2; P = 0.006), and T2DM
(3.8 mmol/L; IQR, 3.4–4.7; P < 0.0001) groups compared
with controls (5.3 mmol/L; IQR, 4.8–5.9) and in the T2DM
group compared with the LADA group (P = 0.02). Low-
density lipoprotein was significantly lower in patients with
T1DM (2.0 mmol/L; IQR, 1.8–2.3; P < 0.0001), LADA (2.4
mmol/L; IQR, 1.8–2.9; P = 0.01), or T2DM (1.8 mmol/L;
IQR, 1.3–2.3; P < 0.0001) compared with healthy controls
(3.0 mmol/L; IQR, 2.7–3.3). High-density lipoprotein was
significantly lower in patients with T2DM (1.0 mmol/L; IQR,
0.9–1.2) compared with healthy controls (1.6 mmol/L; IQR,
1.1–1.9; P < 0.0001) and patients with T1DM (1.6 mmol/L;
IQR, 1.2–2.0; P < 0.0001) or LADA (1.4 mmol/L; IQR,
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TABLE 1. Clinical and Demographic Data in Healthy Controls and Patients With T1DM, LADA, or T2DM
Control (n = 23) T1DM (n = 25) LADA (n = 23) T2DM (n = 36) P
Male, n (%) 11 (47.8) 17 (68.0) 18 (50.0) 14 (52.2) 0.4
Age (y), mean ± SD 54.1 ± 11.1 53.3 ± 11.7 50.5 ± 11.5 57.7 ± 7.5 0.6
Diabetes duration (y), mean ± SD N/A 19.4 ± 7.6* 11.6 ± 9.6 15.1 ± 4.9 <0.0001
BMI (kg/m2), mean ± SD 27.4 ± 4.6 26.8 ± 4.4 27.1 ± 4.4 31.7 ± 5.2*,†,‡ <0.001
HbA1c (%), mean ± SD 5.4 ± 0.2 7.9 ± 1.4*,† 9.7 ± 2.4† 8.2 ± 1.4*,† <0.001
HbA1c (mmol/mol), mean ± SD 35.4 ± 2.9 63.0 ± 15.0*,† 83.0 ± 25.8† 66.0 ± 15.4*,† <0.001
Total cholesterol (mmol/L), median (IQR) 5.3 (4.8–5.9) 4.0 (3.5–4.7)† 4.5 (3.8–5.2)† 3.8 (3.4–4.7)*,† <0.001
HDL (mmol/L), median (IQR) 1.6 (1.1–1.9) 1.6 (1.2–2.0) 1.4 (1.1–1.7) 1.0 (0.9–1.2)*,†,‡ <0.001
Triglycerides (mmol/L), median (IQR) 1.5 (1.0–1.8) 1.0 (0.8–1.4) 1.2 (0.7–2.0) 1.8 (1.1–3.2)*,‡ 0.003
LDL (mmol/L), median (IQR) 3.0 (2.7–3.3) 2.0 (1.8–2.3)† 2.4 (1.8–2.9)† 1.8 (1.3–2.3)† <0.001
NDS, median (IQR) 0.0 (0.0–0.0) 2.0 (0.5–4.5)† 2.0 (0.5–6.0)† 2.0 (1.0–5.0)† <0.001
NSP, median (IQR) 0 2.0 (1.0–7.0)† 4.0 (3.5–8.0)† 2.5 (1.3–7.2)† 0.001
VPT, median (IQR) 5.5 (4.9–10.9) 13.6 (10.3–20.8)† 8.7 (6.1–17.7) 11.1 (10.4–17.3)† 0.01
PMNCV (m/s), median (IQR) 47.7 (45.9–49.4) 42.0 (39.15–43.1)† 42.8 (37.9–44.5)† 44.6 (42.2–46.6) <0.0001
P represents statistical difference among all groups. All symbols represent statistically significant differences. BMI, body mass index;
HDL, high-density lipoprotein; LDL, low-density lipoprotein. Statistically significant differences are in bold.
* Significant difference compared with LADA.
† Significant difference compared with control.
‡ Significant difference compared with T1DM.
TABLE 2. Langerhans Cell Density and Corneal Nerve Parameters in Healthy Controls and Patients With T1DM, LADA, or T2DM
Control (n = 23) T1DM (n = 25) LADA (n = 23) T2DM (n = 36) P
Langerhans cell density (no./mm2), median (IQR)
Mature 3.1 (0.0–9.4) 6.2 (2.3–12.0) 8.3 (3.1–22.5)* 7.5 (2.3–24.5)* 0.059
Immature 17.5 (8.3–42.9) 28.1 (18.7–77.6) 42.7 (31.2–103.1)* 39.3 (11.6–98.1) 0.03
Total 22.5 (9.4–46.9) 34.4 (19.8–95.3)* 47.9 (34.4–138.5)* 51.6 (16.1–107.6)* 0.03
CNFD (no./mm2), median (IQR) 30.2 (28.1–37.5) 23.4 (20.2–28.1)* 22.9 (20.8–27.1)* 26.1 (21.9–30.9)* <0.001
CNBD (no./mm2), median (IQR) 88.8 (71.9–96.9) 44.8 (28.5–61.6)* 54.2 (41.7–69.8)* 48.4 (32.3–75.0)* <0.001
CNFL (mm/mm2), mean ± SD 27.8 ± 4.1 19.1 ± 4.2* 20.3 ± 7.4* 21.3 ± 6.3* <0.001
P represents statistical difference among all groups. Statistically significant differences are in bold.
* Significant difference compared to control.
1.1–1.7; P = 0.001). Triglycerides were significantly higher
in patients with T2DM (1.8 mmol/L; IQR, 1.1–3.2) compared
with patients with T1DM (1.0 mmol/L; IQR, 0.8–1.4; P <
0.0001) or LADA (1.2 mmol/L; IQR, 0.7–2.0; P = 0.03) but
not controls (1.5 mmol/L; IQR, 1.0–1.8; P = 0.07).
Neuropathy Assessment
NDS was significantly higher in T1DM (2.0; IQR, 0.5–4.5; P=
0.01), LADA (2.0; IQR, 0.5–6.0; P = 0.006), and T2DM (2.0;
IQR, 1.0–5.0; P = 0.003) compared with controls and was
comparable among diabetes groups. NSP was significantly
higher in the T1DM (2.0; IQR, 1.0–7.0; P = 0.001), LADA
(4.0; IQR, 3.5–8.0; P = 0.001), and T2DM (2.5; IQR, 1.3–
7.2; P = 0.001) groups compared with healthy controls and
was comparable among the diabetes groups. VPT was signif-
icantly higher in T1DM (13.6; IQR, 10.3–20.8; P < 0.0001)
and T2DM (11.1; IQR, 10.4–17.3; P = 0.002) but not in LADA
(8.7; IQR, 6.1–17.7; P = 0.1) compared with controls (5.5;
IQR, 4.9–10.9). PMNCV was significantly lower in T1DM
(42.0 m/s; IQR, 39.1–43.1; P = 0.002) and LADA (42.8 m/s;
IQR, 37.9–44.5; P = 0.001), but not in T2DM (44.6 m/s; IQR,
42.19–46.6; P = 0.1) compared with healthy controls (47.7
m/s; IQR, 45.9–49.4) (Table 1). The severity of abnormality
in both VPT and PMNCV was indicative of a mild neuropa-
thy.
Corneal Confocal Microscopy
CNFD was significantly lower in T1DM (23.4/mm2; IQR,
20.2–28.1; P < 0.0001), LADA (22.9/mm2; IQR, 20.8–27.1;
P < 0.0001), and T2DM (26.1/mm2; IQR, 21.9–30.9; P =
0.002) compared with controls (30.2/mm2; IQR, 28.1–37.5),
with no significant difference between T1DM and LADA (P
= 0.7), T1DM and T2DM (P = 0.2), or LADA and T2DM
(P = 0.09). CNBD and CNFL were also significantly lower
in T1DM (CNBD: 44.8/mm2, IQR, 28.5–61.6, P < 0.0001;
CNFL: 19.1 mm/mm2 ± 4.2, P < 0.0001), LADA (CNBD:
54.2/mm2, IQR, 41.7–69.8, P < 0.0001; CNFL: 20.3 mm/mm2
± 7.4, P < 0.0001), and T2DM (CNBD: 48.4/mm2, IQR, 32.3–
75.0, P < 0.0001; CNFL: 21.3 mm/mm2 ± 6.3, P < 0.0001)
compared with controls (CNBD: 88.8/mm2, IQR, 71.9–96.9;
CNFL: 27.8 mm/mm2 ± 4.1). There was no significant differ-
ence in CNBD and CNFL between T1DM and LADA (P = 0.1,
P = 0.9), T2DM and LADA (P = 0.4, P = 0.9), or T1DM and
T2DM (P = 0.3, P = 0.7) (Table 2).
Langerhans Cells
Total LC density was significantly higher in patients
with T1DM (34.4/mm2; IQR, 19.8–95.3; P = 0.05), LADA
(47.9/mm2; IQR, 34.4–138.5; P = 0.002), or T2DM
(51.6/mm2; IQR, 16.1–107.6; P = 0.05) compared with
controls (22.5/mm2; IQR, 9.4–46.9) (Table 2, Figs. 1 and 2).
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FIGURE 1. CCM images of a healthy control (A) and age-matched patient with T1DM (B), LADA (C), and T2DM (D).
FIGURE 2. Immature LC density (A), mature LC density (B), and total LC density (C) in controls and patients with T1DM, LADA, or T2DM.
There was no significant difference between T1DM and
LADA (P = 0.1), T2DM and LADA (P = 0.8), or T1DM
and T2DM (P = 0.3). Mature LC density was higher in
patients with LADA (8.3/mm2; IQR, 3.1–22.5; P = 0.01)
or T2DM (7.5/mm2; IQR, 2.3–24.5; P = 0.02) but not in
patients with T1DM (6.2/mm2; IQR, 2.3–12.0; P = 0.1)
compared with controls (3.1/mm2; IQR, 0.0–9.4). There was
no significant difference between T1DM and LADA (P =
0.2), T2DM and LADA (P = 0.8), or T1DM and T2DM (P
= 0.4). Immature LCs were significantly higher in patients
with LADA (42.7/mm2; IQR, 31.2–103.1; P = 0.002), but their
numbers did not differ in patients with T1DM (28.1/mm2;
IQR, 18.7–77.6; P = 0.06) or T2DM (39.3/mm2; IQR, 11.6–
98.1; P = 0.06) compared with controls (17.5/mm2; IQR,
8.3–42.9). Sixty-five percent of controls and 95% of patients
with diabetes had mature LCs in their central cornea. Both
patients and controls had immature LCs in their central
corneas.
There was a significant negative correlation between
CNBD and mature (r = –0.5, P = 0.008), immature (r =
–0.4, P = 0.02), and total (r = –0.5, P = 0.01) LC density
and between CNFL and immature LC density (r = –0.4, P =
0.03) in patients with T1DM. There was no significant asso-
ciation between corneal nerve parameters and LC density in
patients with T2DM and LADA (Table 3).
Neuropathy According to Toronto Consensus
Among Patients With Diabetes
Patients were divided into two groups: those with DPN
(n = 25) and those without DPN (n = 59) according to
the Toronto consensus,24 which requires the presence of
symptoms (abnormal NSP) or signs of neuropathy (NDS
> 2 or VPT > 15) and abnormal peroneal nerve conduc-
tion velocity (PMNCV < 40 m/s). In our cohort, 36% of
subjects with T1DM, 22% of subjects with T2DM, and 34%
of subjects with LADA had DPN, without a significant differ-
ence among the groups (P = 0.4). Considering all patients
with diabetes, CNFD was significantly lower in patients
with DPN (20.8/mm2; IQR, 18.74–26.82) compared with
those without DPN (25.0/mm2; IQR, 21.87–29.16; P = 0.03),
whereas CNBD (with DPN: 52.1/mm2, IQR, 29.27–65.15;
without DPN: 50.0/mm2, IQR, 40.17–67.70; P = 0.7) and
CNFL (with DPN: 18.9 mm/mm2, IQR, 16.32–22.57; with-
out DPN: 20.9 mm/mm2, IQR, 17.18–24.31; P = 0.2) did
not differ significantly. Mature LCs (with DPN: 9.4/mm2,
IQR, 3.51–22.70; without DPN: 6.2/mm2, IQR, 2.08–14.06; P
= 0.2), immature LCs (with DPN: 46.42/mm2, IQR, 25.52–
128.85; without DPN: 39.58/mm2; IQR, 14.06–71.87; P =
0.2), and total LCs (with DPN: 61.2/mm2, IQR, 31.63–148.85;
without DPN: 43.74/mm2, IQR, 17.49–89.58; P = 0.2) did not
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differ significantly between patients with and without DPN.
In patients with DPN, CNBD was inversely correlated with
mature (r = –0.4, P = 0.03), immature (r = –0.5, P = 0.01),
and total LC (r = –0.5, P = 0.007) density.
DISCUSSION
CCM has shown corneal nerve loss in patients with T1DM,25
T2DM,26–28 or LADA.29 Recent studies have shown that
corneal nerve loss may be more severe in patients with
LADA compared with T2DM18 and in patients with T2DM
compared with T1DM.30,31 However, in the current study,
we show comparable corneal nerve loss in patients with
T1DM, T2DM, and LADA, with a significantly lower CNFD in
patients with DPN. The differences in relation to the severity
of corneal nerve loss in different types of diabetes found in
previous studies and in relation to DPNmay reflect the sever-
ity of DPN and the method used to quantify corneal nerve
parameters.28,32,33 In this respect, Andersen et al.28 showed
a reduction in CNFD but no difference in CNBD or CNFL
between patients with and without DPN. However, their
patients with T2DM had excellent glycemic control, and they
used automated corneal nerve quantification which is not as
sensitive in detecting a reduction in nerve branches. Further-
more, the relatively low specificity reported for CCM simply
reflects the fact that small fiber abnormalities detected by
CCM occur earlier than large fiber abnormalities, whereas
the criteria used to define DPN are biased toward the assess-
ment of large fibers.31
Inflammation may play a major role in the development
of diabetic peripheral neuropathy.34 In the present study
we show an increase in LCs in patients with T1DM, T2DM,
or LADA and an association between increased LC density
and reduced CNBD. Studies have suggested a pathophysio-
logical interaction between nerves and LCs,35 and they are
located close to peripheral nerves in the skin and cornea.36
Furthermore, small nerve fibers can influence immune cell
activity by releasing cytokines and neuropeptides.37 LCs also
express neurotrophic factors such as ciliary neurotrophic
factor which can promote nerve regeneration.38 Previous
studies have reported increased LC density and corneal
nerve loss in immune-mediated conditions such as Behçet’s
disease,39 multiple sclerosis,40 and chronic inflammatory
demyelinating polyneuropathy.41 In patients with diabetes,
increased TNF-α42 and corneal4,17 and epidermal13,43 LCs
have been reported. Using first-generation CCM,we reported
an increase in LC density in patients with mild diabetic
neuropathy but did not assess for differences between T1DM
and T2DM.17 In a more recent study, with third-generation
CCM and higher resolution, we have reported an increase in
both mature and immature LCs in children with T1DM.4 In
both studies, there was no association between LC density
and the severity of corneal nerve damage. To our knowl-
edge, our study is the first to report an association between
corneal nerve loss and an increase in LC density in patients
with T1DM but not LADA or T2DM. The differences between
these studies may be attributed to significant differences
in age, duration of diabetes, and sample size. Leppin et
al.15 reported a significant association between increased
corneal dendritic cells and nerve fiber loss in a mouse model
of T1DM, although, Yu et al.44 reported a positive associa-
tion between LCs and corneal nerves. The heterogeneity of
autoimmune diabetes45–47 may also explain differences in
the degree of inflammation among T1DM, LADA, and T2DM.
Hence, the inverse association between LC and corneal nerve
parameters in patients with T1DM could be explained by
an impaired function of antigen-presenting cells. However,
we cannot exclude the effect of disease duration, glycemic
control, and other metabolic abnormalities on this relation-
ship, explaining why we did not find an association between
LC density and corneal nerve parameters in patients with
LADA and T2DM.
Learning from the field of cardiovascular disease, we
know that biomarkers that predict the development of
cardiovascular disease are paramount in the management of
patients at risk.48,49 Studies that assess the utility of CCM in
quantifying LCs in relation to nerve damage may help estab-
lish surrogate imaging markers for diabetic neuropathy.
The limitations of this study include the relatively small
sample size in each group and the cross-sectional nature
of the study, which prevents conclusions regarding cause
and effect between increased LCs and corneal nerve loss in
patients with DPN. The patients had mild DPN; therefore, we
cannot comment on the role of LCs in subclinical or more
advanced DPN. Although large and small fiber measure-
ments were comparable, we acknowledge that differences in
glycemic control, lipid metabolism, and hypoglycemic treat-
ment could have had an impact on our findings.
In conclusion, CCM has identified comparable corneal
nerve loss and an increase in LC density in patients with
T1DM, T2DM, or LADA. There was an association between
increased LCs and corneal nerve loss in T1DM. Larger
longitudinal studies are required to assess the relationship
between LCs and corneal nerves in DPN.
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